Skip to content
Bored Studies
RecruitingPhase 2

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

ADARx Pharmaceuticals, Inc. · NCT06989359

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
45
US sites recruiting
7
Study start
August 28, 2025
Record last updated
October 20, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.

Being studied: ADX-038 Dose Level 2; ADX-038 Dose Level 1

Conditions: IgAN; C3G; Complement-mediated Kidney Disease; IgA Nephropathy (IgAN); IC-MPGN

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Mean eGFR greater than or equal to 30 mL/min/1.73m2
  • Clinical evidence of active kidney disease
  • Treated with supportive care including an ACE inhibitor or ARB if applicable
  • Willing to receive required vaccinations
  • Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy

Exclusion Criteria

  • Hereditary or acquired complement deficiency
  • Kidney transplant or renal replacement therapy
  • History of solid organ transplant
  • Other kidney disease
  • History of recurrent invasive infections
  • Received complement inhibitor treatments
  • Active systemic viral, bacterial, or fungal infection
  • Abnormal liver function

Recruiting US locations

Study contacts (from the official record)

  • Tracy Nguyen · 877-232-7974 · info@adarx.com
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease (NCT06989359) | Bored Studies